SGLT2 inhibitors

SGLT2 inhibitors are a class of medications that block the sodium-glucose co-transporter 2 in the renal proximal tubule, leading to increased glucose excretion in urine and reduced blood glucose levels. They are significant in managing type 2 diabetes and have shown benefits in reducing cardiovascular and renal complications. A key example is empagliflozin, which is associated with a lower risk of heart failure hospitalisation in diabetic patients.